A Study With Darapladib to Collect Tolerability Information
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Subjects will receive their first dose of darapladib in the clinical research unit (CRU), and
the remaining 9 days of dosing will occur at home. Subjects will record any adverse events
throughout the dosing period in a paper diary. Subjects will return to the CRU 10-14 days
after the last dose of darapladib for a follow-up visit. The total study duration for each
subject including the screening, treatment and follow-up periods will be approximately 4
weeks.